A Director at Laboratory is Exercising Options

By Carrie Williams

Yesterday it was reported that a Director at Laboratory (LHResearch Report), Jean-Luc Belingard, exercised options to sell 26,479 LH shares at $77.19 a share, for a total transaction value of $5.02M.

Following Jean-Luc Belingard’s last LH Sell transaction on May 11, 2017, the stock climbed by 48.4%.

See today’s analyst top recommended stocks >>

Based on Laboratory’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.95 billion and quarterly net profit of $227 million. In comparison, last year the company earned revenue of $2.79 billion and had a net profit of $158 million. The company has a one-year high of $196.36 and a one-year low of $140.53. Currently, Laboratory has an average volume of 691.03K.

Jean-Luc Belingard’s trades have generated a -12.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.